In the context of cancer therapy, pharmacologic targeting of p38 and MK2 was shown to enhance anti-leukemic activity of smac-mimetic by potentiating TNF production, TNF-dependent apoptosis, and tumor cell death60. This evidence concerns the gene TNF and neoplasm.